Plantibodies and Plantibody Hybrids as HIV Microbicides
Plantibody 和 Plantibody 杂种作为 HIV 杀微生物剂
基本信息
- 批准号:6444303
- 负责人:
- 金额:$ 30万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-09-01 至 2004-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION: (Provided by Applicant) The objective of this project is to
produce human antibodies and antibody hybrids in plants (plantibodies)) to meet
the market needs (low cost, large capacity) of a vaginal microbicide for
preventing the sexual transmission of human immunodeficiency virus (HIV). Since
the mechanisms of sexual transmission of HIV are not well understood,
plantibodies will be developed to a range of targets that individually or
synergistically may provide protection against mucosal HIV transmission.
Several well-studied monoclonal antibodies to gp160 (2F5, 2G12, 4E10) that have
demonstrated broad neutralizing activity in vitro against primary isolates and
protection in primates will be produced in plants. Since plantibody hybrids may
be less susceptible to gp160 variability or epitope accessibility, two hybrids
will be manufactured in plants: (a) PRO542 which has CD4 replacing the binding
domain of the antibody scaffold; (b) sCD4-17b (CD4 linked to an HIV scFv)
causes a conformation change in gp120 that enables the antibody binding domain
to interact with a previously unexposed, conserved epitope. In addition, an
antibody to CCR5 (PRO140), the HIV co-receptor, will be produced as a
plantibody so that a receptor-targeted strategy can be evaluated. These HIV
plantibodies and plantibody hybrids can be combined with plantibodies against
other sexually transmitted disease pathogens already being produced in plants
by Epicyte for broad-spectrum vaginal protection.
PROPOSED COMMERCIAL APPLICATION: Plant-based production systems offer a unique opportunity to provide large quantities of protective plantibodies and plantibody hybrids at a cost that enables the application of this technology to preventing mucosal transmission of a wide range of infectious pathogens.
描述:(由申请人提供)本项目的目标是
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kevin John Whaley其他文献
Kevin John Whaley的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kevin John Whaley', 18)}}的其他基金
Industrialization of Antibody-based Contraceptive MPTs
抗体避孕MPT产业化
- 批准号:
9624284 - 财政年份:2018
- 资助金额:
$ 30万 - 项目类别:
Industrialization of Antibody-based Contraceptive MPTs
抗体避孕MPT产业化
- 批准号:
10159119 - 财政年份:2018
- 资助金额:
$ 30万 - 项目类别:
Critical Path Project: Mapp66, a Multi-antibody Prevention Product
关键路径项目:Mapp66,多抗体预防产品
- 批准号:
8329740 - 财政年份:2011
- 资助金额:
$ 30万 - 项目类别:
BLOCKING STD PATHOGEN ENTRY WITH MUCOSAL ANTIBODIES
用粘膜抗体阻断性病病原体进入
- 批准号:
6654007 - 财政年份:2002
- 资助金额:
$ 30万 - 项目类别:
Plantibodies and Plantibody Hybrids as HIV Microbicides
Plantibody 和 Plantibody 杂种作为 HIV 杀微生物剂
- 批准号:
6854214 - 财政年份:2002
- 资助金额:
$ 30万 - 项目类别:
BLOCKING STD PATHOGEN ENTRY WITH MUCOSAL ANTIBODIES
用粘膜抗体阻断性病病原体进入
- 批准号:
6602128 - 财政年份:2002
- 资助金额:
$ 30万 - 项目类别:
BLOCKING STD PATHOGEN ENTRY WITH MUCOSAL ANTIBODIES
用粘膜抗体阻断性病病原体进入
- 批准号:
6500706 - 财政年份:2001
- 资助金额:
$ 30万 - 项目类别:














{{item.name}}会员




